World's 1st 'tooth regrowth medicine' to be tested in Japan from Sept. 2024

OSAKA -- Clinical trials of the world's first "tooth regrowth medicine" are set to commence in September at Kyoto University Hospital, researchers announced here on May 2.

Once the medicine's safety is confirmed, it will be given to patients congenitally lacking a full set of teeth to confirm its effectiveness. The researchers hope to commence sale of the medicine in 2030.

Congenital tooth deficiency is believed to affect about 1% of the population. The absence of six or more teeth, a condition known as oligodontia, is believed to be hereditary, and is said to affect about 0.1% of the population.

According to Kitano Hospital in Osaka's Kita Ward, which is involved in the study, the first phase of the clinical trials will run from September this year to August 2025. The medicine will be administered intravenously to healthy individuals to confirm its effectiveness, with 30 males between the ages of 30 and 64 taking part. The subjects must be missing at least one back tooth so that there will be no problem if the medicine takes effect and a tooth begins to grow. No major side effects have been confirmed in animal studies to date.

In the next stage, the medication will be administered at Kitano Hospital to patients with congenital tooth deficiency. Researchers plan to limit the subjects during this phase to those between the ages of 2 to 7 who have at least four teeth missing from birth.

Leave a Comment